6 studies found for:    17215530 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Unknown  SORAVE - Sorafenib and Everolimus in Solid Tumors
Condition: Relapsed and/or Refractory Solid Tumors
Intervention: Drug: Combination of sorafenib and everolimus
2 Completed Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma
Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Temsirolimus;   Drug: Bevacizumab;   Drug: Sunitinib;   Drug: Interferon alpha-2a
3 Recruiting Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma
Condition: Renal Cell Carcinoma
Intervention: Drug: sorafenib+gemcitabine+cisplatin
4 Active, not recruiting Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors
Conditions: Metastatic Renal Cell Carcinoma;   Advanced Refractory Solid Tumors Histologically or Cytologically Confirmed
Intervention: Drug: Association of Bevacizumab (BVC)+ Pazopanib (PZP)
5 Active, not recruiting Chemokines and Renal Cancer
Conditions: Carcinoma;   Carcinoma Renal Cell;   Kidney Neoplasms;   Kidney Diseases;   Chemokines
Intervention: Biological: Biological sample
6 Completed
Has Results
Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer
Condition: Carcinoma, Renal Cell
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006);   Drug: Placebo

Indicates status has not been verified in more than two years